← All trials
NCT06501924
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2025
- Primary completion
- Oct 17, 2025
- Completion date
- Dec 12, 2025
- First posted
- Jul 15, 2024
- Last posted
- Nov 8, 2024
- Enrollment
- 516
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Applied Biology, Inc.Lead sponsor
- Daniel Alain, Inc.Collaborator
- University of Roma La SapienzaOfficial
- Follea International LimitedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.